Table 1 Clinical characteristics of patients with MFN of long bones
Variables | Number (%) | |||||
|---|---|---|---|---|---|---|
Fibrosarcoma (NOS) N = 51 | Fibromyxosarcoma N = 4 | Periosteal fibrosarcoma N = 12 | Malignant fibrous histiocytoma N = 170 | Total | ||
57 | 61 | 48 | 56 | 56 | ||
Age | ≤16 | 1 (2.0%) | 0 (0%) | 2 (16.7%) | 9 (5.3%) | 12 (5.1%) |
17–39 | 11 (21.6%) | 1 (25.0%) | 2 (16.7%) | 28 (16.5%) | 42 (17.7%) | |
40–60 | 16 (31.4%) | 0 (0.0%) | 3 (25.0%) | 54 (31.8%) | 73 (30.8%) | |
>60 | 23 (45.1%) | 3 (75.0%) | 5 (41.7%) | 79 (46.5%) | 110 (46.4%) | |
Race recode | Other | 4 (7.8%) | 0 (0.0%) | 3 (25.0%) | 9 (5.3%) | 16 (6.8%) |
White | 39 (76.5%) | 4 (100.0%) | 9 (75.0%) | 143 (84.1%) | 195 (82.3%) | |
Black | 8 (15.7%) | 0 (0.0%) | 0 (0.0%) | 18 (10.6%) | 26 (11.0%) | |
Sex | Female | 19 (37.3%) | 2 (50.0%) | 6 (50.0%) | 82 (48.2%) | 109 (46.0%) |
Male | 32 (62.7%) | 2 (50.0%) | 6 (50.0%) | 88 (51.8%) | 128 (54.0%) | |
Decade of diagnosis | 1970s | 8 (15.7%) | 0 (0.0%) | 7 (58.3%) | 7 (4.1%) | 22 (9.3%) |
1980s | 7 (13.7%) | 0 (0.0%) | 3 (25.0%) | 30 (17.6%) | 40 (16.9%) | |
1990s | 6 (11.8%) | 0 (0.0%) | 0 (0.0%) | 38 (22.4%) | 44 (18.6%) | |
2000s | 17 (33.3%) | 3 (75.0%) | 1 (8.3%) | 73 (42.9%) | 94 (39.7%) | |
2010s | 13 (25.5%) | 1 (25.0%) | 1 (8.3%) | 22 (12.9%) | 37 (15.6%) | |
Tumor grade | Unknown | 7 (13.7%) | 1 (25.0%) | 6 (50.0%) | 63 (37.1%) | 77 (32.5%) |
Low | 18 (35.3%) | 1 (25.0%) | 3 (25.0%) | 7 (4.1%) | 29 (12.2%) | |
High | 26 (51.0%) | 2 (50.0%) | 3 (25.0%) | 100 (58.8%) | 131 (55.3%) | |
Tumor Size | <5 cm | 27 (52.9%) | 0 (0.0%) | 9 (75.0%) | 83 (48.8%) | 119 (50.2%) |
5 cm-10 | 8 (15.7%) | 0 (0.0%) | 0 (0.0%) | 18 (10.6%) | 26 (11.0%) | |
>10 | 13 (25.5%) | 4 (100.0%) | 2 (16.7%) | 42 (24.7%) | 61 (25.7%) | |
Unknown | 3 (5.9%) | 0 (0.0%) | 1 (8.3%) | 27 (15.9%) | 31 (13.1%) | |
Stage | Unknown | 4 (7.8%) | 0 (0.0%) | 1 (8.3%) | 11 (6.5%) | 16 (6.8%) |
Local | 23 (45.1%) | 2 (50.0%) | 4 (33.3%) | 62 (36.5%) | 91 (38.4%) | |
Region | 16 (31.4%) | 1 (25.0%) | 5 (41.7%) | 62 (36.5%) | 84 (35.4%) | |
distant | 8 (15.7%) | 1 (25.0%) | 2 (16.7%) | 35 (20.6%) | 46 (19.4%) | |
Surgery | No | 13 (19.4%) | 0 (0.0%) | 5 (41.7%) | 38 (22.4%) | 56 (23.6%) |
Yes | 38 (74.5%) | 4 (100.0%) | 7 (58.3%) | 131 (77.1%) | 180 (75.9%) | |
Unknown | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (0.6%) | 1 (0.4%) | |
Radiotherapy | No/Unknown | 36 (70.6%) | 4 (100.0%) | 8 (66.7%) | 133 (78.2%) | 181 (76.4%) |
Yes | 15 (29.4%) | 0 (0.0%) | 4 (33.3%) | 37 (21.8%) | 56 (23.6%) | |
Chemotherapy | No/Unknown | 36 (70.6%) | 3 (75.0%) | 8 (66.7%) | 87 (51.2%) | 134 (56.5%) |
Yes | 15 (29.4%) | 1 (25.0%) | 4 (33.3%) | 83 (48.8%) | 103 (43.5%) | |
Dead | No | 15 (29.4%) | 3 (75.0%) | 3 (25.0%) | 56 (32.9%) | 77 (32.5%) |
Yes | 36 (70.6%) | 1 (25.0%) | 9 (75.0%) | 114 (67.1%) | 160 (67.5%) | |
Tumor sequence | First | 39 (76.5%) | 4 (100.0%) | 12 (100.0%) | 153 (90.0%) | 208 (87.8%) |
≥Second | 12 (23.5%) | 0 (0.0%) | 0 (0.0%) | 17 (10.0%) | 29 (12.2%) | |
5-year OS rate | 31.40% | 50.00% | 58.30% | 40.60% | 39.70% | |
5-year CSS rate | 62.70% | 75.00% | 66.70% | 58.80% | 60.30% | |
10-year OS rate | 11.80% | 50.00% | 50.00% | 23.50% | 22.80% | |
10-year CSS rate | 58.80% | 75.00% | 58.30% | 55.30% | 56.50% | |